Eupraxia Pharmaceuticals (EPRX)
Develops locally delivered, extended-release drug candidates using its Diffusphere microsphere technology.
Something off on this page? Send us feedback.
Develops locally delivered, extended-release drug candidates using its Diffusphere polymer microsphere technology. Its late-stage focus is EP-104GI for eosinophilic esophagitis, while EP-104IAR targets knee osteoarthritis.
Builds locally delivered, extended-release drug candidates around its proprietary Diffusphere polymer microsphere technology. The platform is intended for targeted, localized and extended drug delivery. EP-104GI, its gastrointestinal formulation of fluticasone propionate, is the late-stage focus for eosinophilic esophagitis.
EP-104IAR applies the same technology to an intra-articular formulation, initially for knee osteoarthritis. These are development programs rather than approved products, reflecting a clinical-stage biotechnology model.
Operations have shifted from Victoria to a Vancouver-and-Seattle model, with the chief executive and key clinical, manufacturing, and commercial leaders based in Seattle. The company’s work centers on clinical development of locally delivered drug candidates.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jun 25, 2026 | Oppenheimer | Initiate | Outperform | $17 |
| Jan 15, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $19 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $133.4M · Total debt $1.8M · Total assets $139.6M · Shareholders' equity $131.0M
- Revenue
- $0
- Operating income
- −$18.1M
- Net income
- −$14.5M
No dividends on record.
| Institutions55 holders · as of Mar 31, 2026 | 66.39% | 22.23M ADS | |
| Otherremainder | 33.61% | 11.25M ADS |
33.48M ADS as of Aug 30, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Beutel, Goodman & Co Ltd.Institution | 10.95% | 3.67M ADS | 13Fas of Mar 31, 2026 |
Affinity Asset Advisors, LLCInstitution | 4.75% | 1.59M ADS | 13Fas of Mar 31, 2026 |
Balyasny Asset Management L.P.Institution | 4.03% | 1.35M ADS | 13Fas of Mar 31, 2026 |
Vivo Capital, LLCInstitution | 4.03% | 1.35M ADS | 13Fas of Mar 31, 2026 |
Scotia Capital Inc.Institution | 4.01% | 1.34M ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Sanofi (ADR)
Co-markets Dupixent, an FDA-approved biologic for EoE
- Regeneron
Co-markets Dupixent, an FDA-approved biologic for EoE
- Takeda (ADR)
Markets EOHILIA, an FDA-approved oral EoE treatment
- AstraZeneca (ADR)
Leads Phase 3 EoE development of subcutaneous tezepelumab
- Amgen
Shares tezepelumab development and commercialization economics
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals | $7.50 | +0.81% | $249.4M | — | — | — | — |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Takeda (ADR) | $18.73 | +1.55% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| AstraZeneca (ADR) | $163.26 | +0.99% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Median | 27.5 | 17.0 | 4.1 | +9.7% |